Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Phase II and tumor pharmacodynamic study of gefitinib conducted
September 14th, 2005
A phase II and tumor pharmacodynamic study of gefitinib was conducted. Researchers in Spain conducted a study "to evaluate the antitumor activity and pharmacodynamic/biologic effect of gefitinib 500 mg/day monotherapy in patients with previously treated, advanced breast cancer." "In this phase II multicenter trial, the primary objective was assessment of the tumor response rate with gefitinib; secondary objectives included analysis of the pharmacodynamic and biologic profiles in healthy and tumor tissue," explained J. Baselga and colleagues, Vall d'Hebron University Hospital. "While phosphorylation of mitogen-activated protein...
Source: Vaccine Weekly (2005-09-14)
|
